Evaluation of Etanercept in Patients With Plaque Psoriasis After Stopping Ciclosporin Therapy

• Status: Completed
• Trial end date: 2009-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the use of etanercept as a replacement therapy for ciclosporin in patients with plaque psoriasis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Cyclosporine; Cyclosporins; Etanercept

Criteria

Inclusion Criteria:

• Between age 18 and 70 years

• Active and stable plaque psoriasis with a BSA≥10 or PASI≥10.

Exclusion Criteria:

• Evidence of skin conditions other than psoriasis

• Psoralen plus psoralen + ultraviolet A (PUVA), ciclosporin, acitretin, alefacept, anakinra, or any other systemic anti-psoriasis therapy or disease-modifying antirheumatic drugs (DMARD) with 28 days of screening

• ultraviolet B (UVB) therapy, topical steroids, topical Vitamin A or D analog preparations, or anthralin

• Prior exposure to any TNF-inhibitor. Prior exposure to efalizumab

• Corticosteroid dose of prednisone >10 mg/day

• Serious infection

• Receipt of any live vaccine

• Abnormal hematology or chemistry

• Body mass index (BMI) > 38

• Pregnancy or Breastfeeding

• Significant concurrent medical conditions